Market Place
Sourcing Support
MediWound Announces EscharEx Phase II For Venous Leg Ulcers
10 Oct 2024 //
GLOBENEWSWIRE
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
08 Oct 2024 //
GLOBENEWSWIRE
MediWound to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
MediWound Announces FDA Approval Of NexoBrid® For Pediatric Severe Burns
15 Aug 2024 //
GLOBENEWSWIRE
MediWound Reports Q2 2024 Financial Results And Provides Company Update
14 Aug 2024 //
GLOBENEWSWIRE
MediWound Announces Positive Results From NexoBrid® NEXT Protocol
05 Aug 2024 //
GLOBENEWSWIRE
MediWound to Report Second Quarter 2024 Financial Results
02 Aug 2024 //
GLOBENEWSWIRE
MediWound Publishes EscharEx® Phase II Results For Venous Leg Ulcers
29 Jul 2024 //
GLOBENEWSWIRE
MediWound Secures €16.25M From European Innovation Council
16 Jul 2024 //
GLOBENEWSWIRE
MediWound Announces $25 Million Strategic Private Placement Financing
15 Jul 2024 //
GLOBENEWSWIRE
MediWound Q1 2024 Results And Business Update
29 May 2024 //
GLOBENEWSWIRE
MediWound to Report First Quarter 2024 Financial Results
22 May 2024 //
GLOBENEWSWIRE
MediWound To Present EscharEx® Phase 2 Data At Wound Care Conferences
25 Apr 2024 //
GLOBENEWSWIRE
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
MediWound Announces Results in Head-to-Head Comparison of EscharEx® vs. SANTYL®
12 Feb 2024 //
GLOBENEWSWIRE
MediWound to Participate in Two Upcoming Investor Conferences
05 Feb 2024 //
GLOBENEWSWIRE
MediWound Announces that FDA has Accepted for Review the Supplement to NexoBrid BLA
09 Jan 2024 //
GLOBENEWSWIRE
MediWound Announces Publication of EscharEx® Mechanism of Action Study
21 Dec 2023 //
GLOBENEWSWIRE
MediWound Announces Appointment of Shmulik Hess as Chief Operating Officer
21 Nov 2023 //
GLOBENEWSWIRE
MediWound Reports Third Quarter 2023 Financial Results
21 Nov 2023 //
GLOBENEWSWIRE
MediWound to Report Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
MediWound Announces a Collaboration with PMI for NexoBrid Distribution in Europe
08 Nov 2023 //
GLOBENEWSWIRE
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
11 Oct 2023 //
GLOBENEWSWIRE
MediWound Deploys NexoBrid® for Emergency Supply
09 Oct 2023 //
GLOBENEWSWIRE
MediWound Secures U.S. Department of Defense Funding to Advance NexoBrid
26 Sep 2023 //
GLOBENEWSWIRE
MediWound Announces U.S. Commercial Availability of NexoBrid
21 Sep 2023 //
GLOBENEWSWIRE
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Conference
05 Sep 2023 //
GLOBENEWSWIRE
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
15 Aug 2023 //
GLOBENEWSWIRE
MediWound Reports Second Quarter 2023 Financial Results
15 Aug 2023 //
GLOBENEWSWIRE
MediWound to Report Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
MediWound Announces Commercial Launch of NexoBrid® in Japan
01 Aug 2023 //
GLOBENEWSWIRE
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005
10 Jul 2023 //
GLOBENEWSWIRE
MediWound Receives Positive Scientific Advice from EMA on EscharEx
03 Jul 2023 //
GLOBENEWSWIRE
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Conference
14 Jun 2023 //
GLOBENEWSWIRE
MediWound Reports 1Q 2023 FYR and Provides a Company Update
30 May 2023 //
GLOBENEWSWIRE
MediWound to Report First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
MediWound Announces an Additional $10 Million Award from BARDA
09 May 2023 //
GLOBENEWSWIRE
MediWound to Present Phase 2 EscharEx® Data at the Symposium
26 Apr 2023 //
GLOBENEWSWIRE
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
16 Mar 2023 //
GLOBENEWSWIRE
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
MediWound Expands its Leadership Team to Help Drive Company’s Future Growth
06 Mar 2023 //
GLOBENEWSWIRE
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
23 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces Closing of $27.5M Registered Offering of Ordinary Shares
07 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares
03 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces FDA Approval of NexoBrid® for Severe Thermal Burns in Adults
30 Dec 2022 //
GLOBENEWSWIRE
MediWound`s Biologic Nexobrid (Anacaulase) Receives Approval in the U.S.
28 Dec 2022 //
FDA
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
23 Dec 2022 //
GLOBENEWSWIRE
MediWound Strengthens European Presence of NexoBrid®
20 Dec 2022 //
GLOBENEWSWIRE
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005
19 Dec 2022 //
GLOBENEWSWIRE
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
13 Dec 2022 //
GLOBENEWSWIRE
MediWound Announces a 1-for-7 Reverse Share Split
05 Dec 2022 //
GLOBENEWSWIRE
MediWound Reports Third Quarter 2022 Financial Results
15 Nov 2022 //
GLOBENEWSWIRE
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift
09 Nov 2022 //
GLOBENEWSWIRE
MediWound Announces Formation of Strategic Advisory Board
25 Oct 2022 //
GLOBENEWSWIRE
MediWound`s EscharEx Featured in Oral and Poster Presentations at SAWC
18 Oct 2022 //
GLOBENEWSWIRE
MediWound Announces Closing of Concurrent Registered Direct & Private Offerings
07 Oct 2022 //
GLOBENEWSWIRE
MediWound Announces Concurrent Registered Direct and Private Placement
22 Sep 2022 //
GLOBENEWSWIRE
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid
20 Sep 2022 //
GLOBENEWSWIRE
